Tuesday 30th July 2013
|Text too small?|
Ryman Healthcare, whose shares are sitting at a record high after climbing 56 percent this year, trading in the first quarter was in line with the retirement village operator's target's and ahead of the same period on 2012.
"We have reviewed the first quarter's trading, and I'm pleased to advise that we are ahead of last year, and trading in line with our expectations" chairman David Kerr told shareholders at their annual meeting.
The shares edged up 0.6 percent to $7.12 on the NZX, which is 1 cent below the record high charted last week. The shares have climbed for more than 10 years in line with a decade of earnings growth. The stock is rated a 'hold' based on the consensus of six analysts surveyed by Reuters, having moved above the median target price of $6.60.
Kerr said the company is set to enjoy "30 years of exceptional demographic growth" given government forecasts are for the number of New Zealanders aged over 75 to almost triple to 731,000 over the next thirty years, with similar growth expected in the Australian state of Victoria, where its first Melbourne village is due to open in April 2014.
Comprehensive Company Analysis on Ryman Healthcare
The report consists of Business Description, Highlights, Industry overview and Competitive Positioning, Financial Analysis, Management & substantial investor overview, Investment Risks, Market consensus and complete with information on Historical 5 years Income, Balance Sheet and Cash Flow statements. Total 18 pages.
No comments yet
Ryman's dip a buying opportunity as Australian expansion looms, First NZ says
Ryman Healthcare Limited
Ryman boosts FY profit 13 percent as fee income jumps, portfolio value climbs
Ryman Healthcare first-half profit rises 15 percent
Ryman's 1st Qtr ahead of last year; 28th village in Petone
Ryman may seek ASX listing as shares reach record high, profits rise
Ryman shares reach record high as profits rise
Ryman posts record FY profit, beats guidance, on strong demand for units
Ryman posts 15% gain in first-half earnings on sales growth, affirms FY guidance